Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will release financial
results for the fourth quarter and fiscal year ended December 31, 2008
on Thursday, March 26, 2009, prior to the opening of the U.S. financial
markets. A conference call will be held at 8:30 a.m. Eastern Time.
What: Fourth Quarter and Fiscal Year 2008 Financial Results
When: Thursday, March 26, 2009 at 8:30 am Eastern Time
How: Domestic participants can access the call by dialing
1-800-531-3039. International participants are asked to dial
1-847-413-4850. The passcode number for the call is 24136968. The call
will also be webcast through the Company’s website at www.oscient.com.
Contact: Chris Taylor, 781-398-2466
A replay will be available two hours after the conclusion of the call
until April 2, 2009. Domestic participants can access the replay by
dialing 1-888-843-8996, while international participants are asked to
dial 1-630-652-3044. The conference ID number for the replay is
24136968. A replay will also be available through www.oscient.com.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical
company marketing two FDA-approved products in the United States: ANTARA®
(fenofibrate) capsules, a cardiovascular product and FACTIVE®
(gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is
indicated for the adjunct treatment of hypercholesterolemia (high blood
cholesterol) and hypertriglyceridemia (high triglycerides) in
combination with diet. FACTIVE is approved for the treatment of acute
bacterial exacerbations of chronic bronchitis and community-acquired
pneumonia of mild to moderate severity. Oscient promotes ANTARA and
FACTIVE through a national sales force calling on primary care
physicians, cardiologists, endocrinologists and pulmonologists.
For important information regarding the safety and use of ANTARA and
FACTIVE, please see the full prescribing information available at www.antararx.com
and www.factive.com.
For a complete description of the risks associated with our business
please refer to the Company’s Quarterly Report on Form 10-Q for the
quarter ending September 30, 2008 and in other filings that we may make
with the Securities and Exchange Commission from time to time.
Oscient Pharmaceuticals Corporation
Chris Taylor, 781-398-2466
